Artículo de revista
Chitosan-based nanoparticles for Intracellular delivery of ISAV fusion protein cDNA into melanoma cells: a path to develop oncolytic anticancer therapies
Fecha
2020Registro en:
Mediators Inflamm. (2020): 8680692
10.1155/2020/8680692
Autor
Robles Planells, Claudia
Sánchez-Guerrero, Giselle
Barrera Ávalos, Carlos
Matiacevich, Silvia
Rojo, Leonel E.
Pavéz, Jorge
Salas Huenuleo, Edison
Kogan, Marcelo J.
Escobar Álvarez, Alejandro
Milla, Luis A.
Fernández, Ricardo
Imarai, Mónica
Spencer, Eugenio
Huidobro Toro, Juan Pablo
Acuña Castillo, Claudio
Institución
Resumen
Oncolytic virus therapy has been tested against cancer in preclinical models and clinical assays. Current evidence shows that viruses induce cytopathic effects associated with fusogenic protein-mediated syncytium formation and immunogenic cell death of eukaryotic cells. We have previously demonstrated that tumor cell bodies generated from cells expressing the fusogenic protein of the infectious salmon anemia virus (ISAV-F) enhance crosspriming and display prophylactic antitumor activity against melanoma tumors. In this work, we evaluated the effects of the expression of ISAV-F on the B16 melanoma model, both in vitro and in vivo, using chitosan nanoparticles as transfection vehicle. We confirmed that the transfection of B16 tumor cells with chitosan nanoparticles (NP-ISAV) allows the expression of a fusogenically active ISAV-F protein and decreases cell viability because of syncytium formation in vitro. However, the in vivo transfection induces a delay in tumor growth, without inducing changes on the lymphoid populations in the tumor and the spleen. Altogether, our observations show that expression of ISAV fusion protein using chitosan nanoparticles induces cell fusion in melanoma cells and slight antitumor response.